Moreover, as shown in our study, patients with prostate cancer and diabetes had lower PSA levels; hence, reduced sensitivity of PSA might be the reason behind the reported protective effect or lower incidence, indicating a diagnostic bias rather than biological protection. This evidence concerns the gene KLK3 and prostate carcinoma.